A recent study reported that administration of an interleukin-6 receptor antagonist (tocilizumab) to patients with severe COVID-19 provided a therapeutic benefit, and more patients are being enrolled in clinical trials testing the efficacy of this agent [36]. Here, IL6R is linked to COVID-19.